Clinical trials: Oncologic
Cancer
PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy
Researchers are trying to determine the side effects on the heart from immune checkpoint inhibitor (ICI) treatment in patients with cancer.
- Trial name
- NCT04538950
- Testing
- PET/CT, radioactive drug (tracer)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
Breast Cancer
Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.
By leveraging a community-based, cancer-specific electronic healthcare record for this study, we aim to understand treatment patterns and clinical outcomes among patients with HR+/HER2- mBC who received care within the context of…
- Trial name
- NCT04460911
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- Pfizer
Ovarian Cancer, Epithelial Ovarian Cancer
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ARIEL2 (NCT01891344)
- Testing
- Oral rucaparib
- Where
- 75 sites in United States, Australia and 4 more
- Volunteers
- 491 people
- Sponsor
- pharmaand GmbH
Non-small Cell Lung Cancer, Lung Cancer
Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease
Nivolumab releases the inhibition of the immune system against human cancers. Dramatic and sustained activity has been observed in advanced lung cancer. Ablation may stimulate the immune system by exposing new tumor antigens.
- Conditions
- Non-small Cell Lung Cancer, Lung Cancer, Metastatic Lung Cancer, NSCLC
- Trial name
- NCT02469701
- Testing
- nivolumab and ablation
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- howard safran
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer
This is a 2-part study in patients with epidermal growth factor receptor mutation positive (EGFRm+) non-small cell lung cancer (NSCLC) whose disease has progressed on treatment with an epidermal growth factor receptor…
- Trial name
- NCT02163733
- Testing
- AZD9291 tablets, Pharmacokinetic sampling - AZD9291, Dietary Fasted
- Where
- 13 sites in France, South Korea and 2 more
- Volunteers
- 38 people
- Sponsor
- AstraZeneca
Clinical Trials, Immunotherapy
Promoting INformed Approaches in Precision Oncology and ImmuNoTherapy
The purpose of the research is to: develop an educational website to empower Black and African American cancer patients to make informed decisions about personalized cancer treatment and clinical trials.
- Trial name
- PINPOINT (NCT05034289)
- Testing
- PINPOINT Digital Educational Tool
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Adenocarcinoma, Gastric, Neoplasm, Breast
DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein
HER2-positive cancer is a cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). HER2 promotes the growth of certain cancer cells.
- Trial name
- NCT03368196
- Testing
- DS-8201a
- Where
- 2 sites in Taiwan
- Volunteers
- 12 people
- Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
Cardiotoxicity, Risk Factor, Cardiovascular
Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
Investigators will evaluate the safety, tolerability, and feasibility of a risk-guided cardioprotective treatment strategy with carvedilol, as compared to usual care, in breast cancer patients undergoing treatment with…
- Conditions
- Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer
- Trial name
- CCTGuide Pilot (NCT04023110)
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Non Small Cell Lung Cancer
Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC
This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior…
- Trial name
- NCT02197247
- Testing
- Pharmacokinetic sampling - AZD9291, Rifampicin, AZD9291 tablet dosing
- Where
- 18 sites in United States, Netherlands and 4 more
- Volunteers
- 41 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
The purpose of this study is to examine the combination of one standard treatment for lung cancer plus an additional drug, hydroxychloroquine.
- Conditions
- Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT01649947
- Testing
- Paclitaxel, Carboplatin, Hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Rutgers, The State University of New Jersey
Oncology
Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies
This is the first study to test Sym013 (Pan-HER) in humans. The primary purpose of this study is to see if Sym013 is safe and effective for patients with advanced epithelial malignancies without available therapeutic options.
- Trial name
- NCT02906670
- Testing
- Sym013
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Symphogen A/S
Lung Cancer, Chemotherapy-Induced Thrombocytopenia
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung…
- Conditions
- Lung Cancer, Chemotherapy-Induced Thrombocytopenia, Non-Small Cell Lung Cancer, Cancer
- Trial name
- NCT00413283
- Testing
- Romiplostim, Gemcitabine, Carboplatin
- Where
- 113 sites in United States, Austria and 6 more
- Volunteers
- 63 people
- Sponsor
- Amgen
Non-Small Cell Lung Cancer
Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer
In a previous phase II study, patients with pathological stage IIIb (without pleural effusion) NSCLC were treated with concurrent cisplatin and etoposide plus thoracic radiotherapy followed by 3 cycles of consolidation therapy…
- Trial name
- NCT00216125
- Testing
- Cisplatin, Etoposide, Radiation
- Where
- 15 sites in United States
- Volunteers
- 243 people
- Sponsor
- Nasser Hanna, M.D.
Pediatric Oncology, Quality of Life
SPARK Symptom Screening and Feedback to Providers
Supportive care Prioritization, Assessment and Recommendations for Kids (SPARK) is a web-based application which builds upon the Symptom Screening in Pediatrics Tool (SSPedi) and consists of two components: (1) a symptom…
- Trial name
- NCT03593525
- Testing
- SPARK
- Where
- Canada
- Volunteers
- 345 people
- Sponsor
- The Hospital for Sick Children
Ovarian Cancer, Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)
Patients enrolled into this study will be stratified into 3 groups based on gene mutations identified in their tumor tissue. The purpose of this study is to evaluate patient response to maintenance treatment with rucaparib versus…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ARIEL3 (NCT01968213)
- Testing
- Rucaparib
- Where
- 96 sites in United States, Australia and 9 more
- Volunteers
- 564 people
- Sponsor
- pharmaand GmbH
Pediatric Cancer, Quality of Life
Symptom Screening Linked to Care Pathways
Most children with cancer survive because they are given intensive treatments, but unfortunately, these treatments are associated with distressing symptoms.
- Trial name
- NCT04614662
- Testing
- SPARK Symptom Screening Linked to Feedback to Providers
- Where
- 21 sites in United States, Canada
- Volunteers
- 445 people
- Sponsor
- The Hospital for Sick Children
DCIS
Impact of Radiation Therapy on Breast Conservation in DCIS
Large regional variation exists in the use of radiotherapy after breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS).
- Trial name
- NCT02248662
- Where
- 4 sites in United States
- Volunteers
- 3,436 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer, Influenza Viral Infections
Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy
The safety and immunogenicity of high dose influenza vaccine has not been studied in young patients receiving chemotherapy. This study will evaluate and compare the immunogenicity and safety of high dose influenza to standard…
- Trial name
- IMMUNE (NCT01666782)
- Testing
- Standard Trivalent Influenza Vaccine, High-Dose Influenza Vaccine
- Where
- 2 sites in United States
- Volunteers
- 105 people
- Sponsor
- Saad Jamshed MD
Chemotherapy-Induced Nausea and Vomiting
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
The hypothesis is that the substitution of multi-day oral aprepitant with (intravenous) IV fosaprepitant, in combination with a 5-HT3 receptor antagonists (5HT3RA) + dexamethasone will provide comparable protection from 5 day…
- Trial name
- NCT01736917
- Testing
- Fosaprepitant, Dexamethasone, 5HT3
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- Lawrence Einhorn
Chemotherapy-Induced Nausea and Vomiting
Observational Study on the Use of Akynzeo® in Patients Receiving HEC
This Canadian, multi-centre, prospective, observational real-world study is designed to collect patient-reported outcome data on the use of Akynzeo® (netupitant/palonosetron) for the prevention of nausea and vomiting in oncology…
- Trial name
- EVOLVE_CINV (NCT03649230)
- Testing
- 300mg netupitant/0.5mg palonosetron hydrochloride
- Where
- 17 sites in Canada
- Volunteers
- 207 people
- Sponsor
- Purdue Pharma, Canada